aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
ElevateBio is a cell and gene therapy company focused on developing, manufacturing, and commercializing life-transforming medicines. By partnering with innovative scientists and inventors, ElevateBio integrates all elements of R&D into a centralized facility, enabling the rapid translation of research into commercially viable therapies for severe medical conditions.
ElevateBio has achieved significant milestones in the biotech industry, contributing to advancements in cell and gene therapy. The company's centralized approach has streamlined the development process, accelerating the availability of critical treatments for patients.
Operating Status
Active
Ownership Type(s)
Venture Capital, Equity
Main Product(s)
Cell Therapy, Gene Therapy
Technology
Biotech
Tags
Healthtech
Model Types
Platform
Revenue Type(s)
Consulting, Licensing
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was ElevateBio founded?
ElevateBio was founded in 2017.
Where is ElevateBio’s headquarters located?
ElevateBio’s headquarters is located in Cambridge, MA, US.
When was ElevateBio’s last funding round?
ElevateBio’s most recent funding round was for $401M (USD) in May 2023.
How many employees does ElevateBio have?
ElevateBio has 375 employees as of Feb 5, 2024.
How much has ElevateBio raised to-date?
As of July 05, 2023, ElevateBio has raised a total of $1.2B (USD) since May 24, 2023.
Add Comparison
Total Raised to Date
$1.2B
USD
Last Update May 24, 2023
Last Deal Details
$401M
USD
May 24, 2023
Series D
Total Employees Over Time
375
As of Feb 2024
ElevateBio Address
Main Street
Cambridge,
Massachusetts
02138
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts